Biotechnology
Fast therapeutic insights with the in vivo data you need
Get robust and translatable preclinical data with our world-leading expertise and innovative approach
We help our global biotech partners gain early in vivo advances to inform and enrich their drug and therapeutic pipeline in short timeframes (weeks). We combine the inherent advantages of C. elegans as a model organism, with our world-leading expertise for validated, regulation-free testing with human translatability. We effectively build on in vitro studies, de-risk your project, and reduce the need for mammalian testing.
Unique technology and expertise
Our unique automated VivoScan™ and WormGazer™ technology provide rich multi-end point in vivo data to help you generate IP for your therapeutics. You partner with our interdisciplinary team who bring 80+ years joint experience to enable the optimal assay design using C. elegans as a model.
We work efficiently to bring you diverse data to meet your requirements for efficacy, early toxicology, phenotypic and functional end-points, drug combinations, mechanism of action, target validation and identification.
Our advantage for ageing and longevity studies:
“We have formed an incredible partnership, …with novel information on our formulations. All of this will be reflected in the publications of several papers and the filing of several patents. We hope to maintain this collaboration in future projects and keep developing new formulations to help human health.”
Gerald DaRd
Managing Director,
AB Biotek HNH
Case Study: Measuring efficacy to slow ageing for drug discovery biotech Five Alarm Bio
Five Alarm Bio, a UK drug discovery startup focussing on the underlying mechanisms of ageing to develop therapeutics for age-related disease, works with Magnitude Biosciences to test their compound, FAB001, to test their hypothesis on the nature of ageing.
© 2025 Magnitude Biosciences Ltd.
Registered in England and Wales under Company Number 11579884. All rights reserved.